Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Gene Therapy for Hereditary Angioedema
July 01, 2021 01:00 ET
|
Orchard Therapeutics (Europe) Limited
Highlights the broader potential of Orchard’s ex vivo HSC gene therapy platform approach in new and larger indications Reinforces Pharming’s commitment to the HAE community and utilizes its relevant...
Orchard Therapeutics Announces Regulatory and Clinical Updates for Lead Gene Therapy Programs
June 29, 2021 07:00 ET
|
Orchard Therapeutics (Europe) Limited
Expected clinical package for OTL-200 BLA for MLD using data from existing patients clarified with FDA Guidance obtained on design of OTL-203 global registrational trial for MPS-IH Enrollment goal...
Orchard Therapeutics Reports First Quarter 2021 Financial Results and Provides Recent Business Updates
May 13, 2021 07:00 ET
|
Orchard Therapeutics (Europe) Limited
Commercial Activities Advancing for Upcoming Launch of LibmeldyTM (atidarsagene autotemcel) for Eligible Patients with Early-onset MLD in Germany Update on OTL-200 U.S. BLA Filing Strategy for...
Orchard Therapeutics Announces New England Journal of Medicine Publication of HSC Gene Therapy Data for ADA-SCID
May 11, 2021 06:00 ET
|
Orchard Therapeutics (Europe) Limited
100% overall survival and ≥95% event-free survival observed at two and three years following one-time treatment with lentiviral HSC gene therapy 50 total participants represent largest published...
Orchard Therapeutics Announces Multiple Presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy
April 28, 2021 07:01 ET
|
Orchard Therapeutics (Europe) Limited
Seven abstracts accepted show the potential of HSC gene therapy to transform the treatment of multiple severe rare disorders First peer-reviewed presentation from company’s work in transduction...
Orchard Therapeutics Reports 2020 Financial Results and Reviews Recent Accomplishments
March 02, 2021 07:00 ET
|
Orchard Therapeutics (Europe) Limited
$150M Strategic Financing Supports Execution into the First Half of 2023 OTL-203 Achieves Proof of Concept (POC) in MPS-I Hurler Syndrome (MPS-IH); Registrational Trial Planned to Initiate by...
Orchard Therapeutics to Present at Multiple Investor Conferences in March 2021
February 25, 2021 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the...
Orchard Therapeutics Announces Interim Data for OTL-203 Showing Positive Clinical Results in Multiple Disease Manifestations of Mucopolysaccharidosis Type I Hurler Syndrome (MPS-IH)
February 09, 2021 07:00 ET
|
Orchard Therapeutics (Europe) Limited
All eight patients treated with OTL-203 show stable cognitive function, motor function and growth within the normal range at multiple data points post-treatment Supportive initial OTL-201 biomarker...
Orchard Therapeutics Announces $150 Million Strategic Financing
February 05, 2021 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that it has executed a securities purchase agreement to raise...
Orchard Therapeutics Appoints Braden Parker as Chief Commercial Officer
January 29, 2021 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the appointment of Braden Parker to the role of...